Cureety Buys Reimagine Care, Betting Consolidation Solves Oncology's Staffing Squeeze

Cureety announced Wednesday it has acquired Reimagine Care, combining two AI-driven oncology platforms into a network now covering more than 250 cancer centers and over 100,000 patients across five countries. Financial terms were not disclosed.

The thesis behind the deal is straightforward. Cancer treatment has grown more personalized and more complex, but the clinical infrastructure supporting patients between appointments has not kept pace. Oncology teams are managing larger patient populations with the same or fewer resources. Something has to close that gap, and both companies are betting AI triage is the answer.

Cureety built its platform specifically for oncology, embedding therapy-specific monitoring and triage intelligence that helps care teams flag deterioration and prioritize patients. Reimagine Care, a 2025 Fierce 15 honoree, took a different approach: it partners with health systems to act as an extension of the cancer center itself, offering a virtual care center and an AI-enabled assistant called Remi for round-the-clock triage. The company's platform reportedly resolves 95% of patient needs virtually, a figure that speaks directly to the labor-saving pitch underpinning this entire category.

Reimagine Care CEO Dan Nardi framed the acquisition as an extension of work already underway. His company has spent a decade, in his words, "making cancer treatment extraordinarily more sophisticated," but the infrastructure gap around those treatments hasn't closed at the same pace. "That gap becomes harder to defend as therapies become more complex," Nardi told Fierce Healthcare. "If we know what treatment a patient is receiving and understand the risks associated with it, we should be able to recognize when something is changing and respond before that patient ends up in the emergency department or requires an unscheduled visit."

Nardi credited Cureety with building deep intelligence around the specific nuances of individual therapies. Pairing that with Reimagine Care's ability to engage patients continuously through an AI-powered layer, he said, creates "an opportunity to make continuous care much more clinically meaningful and scalable."

The Clinical Case for Consolidation

Cureety COO Misha Kaur offered a more grounded take on where AI actually earns its keep in oncology. Some of the technology's most valuable applications, she said, "may actually be quite unglamorous." Asking useful questions. Recognizing when a patient deviates from baseline. Not exactly the stuff of splashy demos.

"That is what is interesting about bringing in Reimagine Care's AI capabilities with Cureety's clinical rigor," Kaur said. "The test is not whether AI can have an impressive conversation. It is whether the right human enters the conversation at the right moment with enough context to do something useful." The goal, she added, is not to replace human care with technology, but to make human care more timely, informed, and available when it matters.

That framing matters for how investors should read this deal. The value proposition isn't a chatbot that mimics empathy. It's a triage layer that reduces unnecessary escalations and directs scarce clinical attention to patients who actually need it. Reimagine Care's own data backs the case. During its initial rollout with Moffitt Cancer Center, announced in May, the program logged nearly 7,000 patient interactions. Ninety-seven percent were resolved independently without escalating to a provider. Ninety-four percent of symptom management situations were handled virtually. Only 2.4% of interactions resulted in an emergency department referral.

Those numbers are the real product here, not the AI assistant branding. Health systems facing workforce shortages and rising oncology caseloads have a clear financial incentive to adopt tools that keep patients out of the emergency department. Every avoided ED visit is a cost saved for the system and a data point that makes the platform easier to sell into the next hospital contract.

Health tech M&A has been active this year, and this deal fits a familiar pattern: pair a clinically rigorous, therapy-specific platform with a company that has already built patient-facing engagement infrastructure at scale. Neither company disclosed the size of the transaction, which is typical for private health tech deals of this nature, but the combined footprint gives some sense of scale. A network spanning five countries and more than 250 cancer centers is not a pilot program anymore. It's an operating business with real distribution.

The Bottom Line

The deal doesn't come with a purchase price, so investors can't yet model return on capital directly. What they can assess is the strategic logic, and it holds up reasonably well. Oncology is one of the few therapeutic areas where treatment complexity, patient volume, and workforce constraints are all rising simultaneously. That combination creates durable demand for tools that triage effectively rather than just engage patients superficially.

The risk sits in execution and adoption speed. Health systems move slowly, procurement cycles are long, and reimbursement pathways for virtual oncology support remain uneven across markets. Cureety and Reimagine Care will need to prove that the combined platform's resolution rates hold up at scale, not just in a single pilot with Moffitt. The Moffitt data is encouraging, but one health system's experience isn't a guarantee of generalizability across 250 cancer centers with varying clinical protocols and patient populations.

Watch for follow-on funding rounds, additional health system partnerships, and whether Cureety discloses revenue or valuation metrics as it integrates Reimagine Care's technology. Consolidation in oncology AI is likely to continue, and this deal is a useful marker of where the category's economics are heading: not toward flashier conversational AI, but toward measurable reductions in unnecessary clinical escalations. That's a narrower, less glamorous bet, but it's also the one with a clearer path to reimbursement and health system budgets.